ANGLE’s Parsortix® technology demonstrated for use in Melanoma
Abraham Darwyne
Company News - 3 min
09:09, 7th November 2019

ANGLE’s (AGL) FOLLOW technology, Parsortix® predicted melanoma relapse earlier than the standard of care imaging.

Angle said that it was demonstrated in a study that the Parsortix® system could be used as a liquid biopsy to investigate prediction and monitoring of therapy responses for melanoma patients.

The University Medical Centre Hamburg-Eppendorf (UKE), published the results in the renowned peer-reviewed medical journal, Cancers, in late October.

The publication stated "reliable biomarkers, which allow the prediction of therapeutic response and/or the development of therapeutic resistance as early as possible, are urgently needed.''

Shares in ANGLE were trading 2.17% higher at 70.5p on Thursday morning

ANGLE said that the development holds the potential to shift current treatment options for melanoma, opening up the potential for Parsortix to be used.

ANGLE's Founder and Chief Executive, Andrew Newland reiterated the need for reliable biomarkers in melanoma and said: “Initially, these can be used in drug trials where the detection of likely responders to the drug is essential and a key commercial need for pharma companies.”

He added: “Ultimately there is the potential for routine clinical use as a companion diagnostic in melanoma."

The study used Parsortix over a five-year period, with follow-up in some cases for three years, the results showing that Parsortix can harvest circulating tumor cells (CTCs) from some melanoma patients, where other cell surface marker dependent systems are unable to do so.

Follow News & Updates from ANGLE here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist